JO3459B1 - تركيبات صيدلانية لعلاج مرض الزهايمر - Google Patents

تركيبات صيدلانية لعلاج مرض الزهايمر

Info

Publication number
JO3459B1
JO3459B1 JOP/2013/0248A JOP20130248A JO3459B1 JO 3459 B1 JO3459 B1 JO 3459B1 JO P20130248 A JOP20130248 A JO P20130248A JO 3459 B1 JO3459 B1 JO 3459B1
Authority
JO
Jordan
Prior art keywords
alzheimer
disease
treatment
pharmaceutical formulations
span
Prior art date
Application number
JOP/2013/0248A
Other languages
English (en)
Inventor
Schmidt Ellen
Areberg Johan
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3459(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of JO3459B1 publication Critical patent/JO3459B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يصف الاختراع الحالي طرق لمعالجة حالة عته تتضمن جرعة يومية فعالة من <span dir="LTR">N-(2-(6-fluoro-lH-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropoxy)benzylamine </span> لتحسين أو لزيادة تأثير مثبط أسيتيل كولينستيراز.
JOP/2013/0248A 2012-09-09 2013-08-21 تركيبات صيدلانية لعلاج مرض الزهايمر JO3459B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US201361782084P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3459B1 true JO3459B1 (ar) 2020-07-05

Family

ID=49118521

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0248A JO3459B1 (ar) 2012-09-09 2013-08-21 تركيبات صيدلانية لعلاج مرض الزهايمر

Country Status (33)

Country Link
US (4) US9375418B2 (ar)
EP (1) EP2892563B1 (ar)
JP (2) JP6693744B2 (ar)
KR (2) KR20150065680A (ar)
CN (1) CN104619344A (ar)
AP (1) AP2015008306A0 (ar)
AU (1) AU2013311573B2 (ar)
BR (1) BR112015005117B1 (ar)
CA (1) CA2883751C (ar)
CL (1) CL2015000578A1 (ar)
CY (1) CY1121062T1 (ar)
DK (1) DK2892563T3 (ar)
EA (1) EA030448B1 (ar)
ES (1) ES2703630T3 (ar)
GE (1) GEP201706776B (ar)
HR (1) HRP20182069T1 (ar)
IL (1) IL237369B (ar)
JO (1) JO3459B1 (ar)
LT (1) LT2892563T (ar)
MX (1) MX368305B (ar)
MY (1) MY182539A (ar)
NI (1) NI201500031A (ar)
NZ (1) NZ630589A (ar)
PL (1) PL2892563T3 (ar)
PT (1) PT2892563T (ar)
RS (1) RS58104B1 (ar)
RU (1) RU2675786C2 (ar)
SG (1) SG11201501774QA (ar)
SI (1) SI2892563T1 (ar)
SM (1) SMT201800678T1 (ar)
TN (1) TN2015000076A1 (ar)
TW (1) TWI632909B (ar)
WO (1) WO2014037532A1 (ar)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
EA201790600A1 (ru) 2014-09-12 2017-07-31 Янссен Фармацевтика Нв Модулирующие p2x7 n-ацил-триазолопиразины
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
WO2016179566A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Methods of treating a neurodegenerative disease
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
ES2949288T3 (es) * 2016-04-26 2023-09-27 H Lundbeck As Uso de un inhibidor de acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con enfermedad de Parkinson
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
HUE050819T2 (hu) 2016-05-18 2021-01-28 Suven Life Sciences Ltd Tiszta 5-HT6 receptor antagonisták kombinációja acetilkolinészteráz inhibitorokkal
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
SG11201909895UA (en) * 2017-05-24 2019-11-28 H Lundbeck As Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
WO2020065614A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CN113164459B (zh) 2018-09-28 2024-09-03 詹森药业有限公司 单酰基甘油脂肪酶调节剂
ES3037365T3 (en) 2019-09-30 2025-10-01 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
EP3960174B1 (en) 2020-08-28 2024-10-30 Westfälische Wilhelms-Universität Münster Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use
CN121013715A (zh) * 2024-03-22 2025-11-25 艾瑞克·奎因 镁和利多卡因组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
AU685837B2 (en) 1993-09-01 1998-01-29 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-HT1D selectivity
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
WO1999016746A1 (en) 1997-09-29 1999-04-08 Aventis Pharmaceuticals Inc. Aminoalkylphenol derivatives and related compounds
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DE69930308T2 (de) 1998-12-11 2006-11-30 Virginia Commonwealth University Selektive 5-ht 6-rezeptor-liganden
AP2001002228A0 (en) 1999-01-13 2001-09-30 Millenium Pharmaceuticals Inc Functionalized heterocycles as chemokine receptor modulators.
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CZ305838B6 (cs) 2001-03-29 2016-04-06 Eli Lilly And Company N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
RU2252936C2 (ru) 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
ATE509636T1 (de) 2006-06-23 2011-06-15 Esteve Labor Dr Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
JP2013500268A (ja) * 2009-07-23 2013-01-07 シャイア エルエルシー ガランタミンアミノ酸およびペプチドプロドラッグならびにその使用
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
JP2019059760A (ja) 2019-04-18
BR112015005117B1 (pt) 2022-06-21
JP6693744B2 (ja) 2020-05-13
TN2015000076A1 (en) 2016-06-29
NZ630589A (en) 2015-12-24
AU2013311573B2 (en) 2017-10-12
EA030448B1 (ru) 2018-08-31
LT2892563T (lt) 2019-01-10
CA2883751A1 (en) 2014-03-13
US20160354343A1 (en) 2016-12-08
MY182539A (en) 2021-01-25
TWI632909B (zh) 2018-08-21
EP2892563B1 (en) 2018-11-14
RU2675786C2 (ru) 2018-12-25
KR20200137028A (ko) 2020-12-08
GEP201706776B (en) 2017-11-27
SG11201501774QA (en) 2015-05-28
PT2892563T (pt) 2019-01-10
CN104619344A (zh) 2015-05-13
IL237369B (en) 2018-11-29
US9789085B2 (en) 2017-10-17
MX2015002879A (es) 2015-07-06
US20160256437A1 (en) 2016-09-08
US9375418B2 (en) 2016-06-28
CY1121062T1 (el) 2019-12-11
US9687473B2 (en) 2017-06-27
CA2883751C (en) 2020-11-24
WO2014037532A1 (en) 2014-03-13
CL2015000578A1 (es) 2015-05-15
AU2013311573A8 (en) 2015-03-19
SMT201800678T1 (it) 2019-02-28
JP2015528471A (ja) 2015-09-28
TW201414474A (zh) 2014-04-16
DK2892563T3 (en) 2019-01-21
RU2015107877A (ru) 2016-10-27
IL237369A0 (en) 2015-04-30
BR112015005117A2 (pt) 2017-07-04
EA201590353A1 (ru) 2016-03-31
KR102342127B1 (ko) 2021-12-21
NI201500031A (es) 2016-02-15
ES2703630T3 (es) 2019-03-11
HRP20182069T1 (hr) 2019-02-08
AU2013311573A1 (en) 2015-03-12
PL2892563T3 (pl) 2019-04-30
AP2015008306A0 (en) 2015-03-31
HK1212217A1 (en) 2016-06-10
US20140073681A1 (en) 2014-03-13
MX368305B (es) 2019-09-27
EP2892563A1 (en) 2015-07-15
US10660878B2 (en) 2020-05-26
SI2892563T1 (sl) 2019-02-28
KR20150065680A (ko) 2015-06-15
US20180071254A1 (en) 2018-03-15
RS58104B1 (sr) 2019-02-28

Similar Documents

Publication Publication Date Title
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer&#39;s disease
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer&#39;s disease
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
PH12015502365B1 (en) Bace1 inhibitors
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
EA201790315A1 (ru) Модуляторы x-рецепторов печени
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
EA201590074A1 (ru) Производное бензодиоксола, способ его получения и его применение
MX2016008968A (es) Compuestos organicos.
PH12017501668A1 (en) Bace1 inhibitors
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s
MA37957A1 (fr) Procédés de traitement de la maladie d&#39;alzheimer et compositions pharmaceutiques associées
UA123899U (uk) Застосування солей тіазолію як агентів, що інгібують активність ацетилхолінестерази і бутирилхолінестерази